Results 21 to 30 of about 6,142,918 (314)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort

Medicina, 2022
Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a ...
Irena Conic, Bojan Nedovic, Slavica Stojnev, Ilinka Todorovska, Aleksandra Dimitrijevic, Miljan Krstic, Ivana Djordjevic, Biljana Djordjevic   +7 more
doaj   +1 more source

Progression-free survival and overall survival of the cohort.

, 2022
Progression-free survival and overall survival of the cohort.
Chun-Fu Lin (12174572), Yee Chao (804364), Muh-Lii Liang (11204487), Keng-Li Lan (1459669), Tai-Tong Wong (48446), Feng-Chi Chang (435054), Yu-Mei Kang (12174569), Yi-Yen Lee (271429), Shih-Chieh Lin (63678), Hsin-Hung Chen (789932), Sanford P. C. Hsu (3177300), Yi-Wei Chen (48440)   +11 more
core   +1 more source

Progression-free survival according to MTV.

, 2022
Progression-free survival according to MTV.
Nina Jehanno (11949663), Pierre Payoux (3484706), Daniel Orbach (11949669), Marie-Pierre Castex (11949666), Thomas Mognetti (582844), Corradini Nadège (11949672), Helio Fayolle (11949660), Anne Hitzel (11949675), Valerie Lauwers-Cances (437048)   +8 more
core   +1 more source

Outcome of Primary CNS Lymphoma; A Retrospective Analysis

Asian Pacific Journal of Cancer Care, 2022
Background: Rituximab along with high dose Methotrexate is nowadays the standard of care in treatment of PCNSL. We report the retrospective analysis of PCNSL patients who were treated with and without Rituximab at Aga Khan University Hospital, Karachi ...
Mehwish Shahzadi, Daniyaal Ahmed, Sobia Sawani, Munira Moosajee   +3 more
doaj   +1 more source

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]

JNCI: Journal of the National Cancer Institute, 2009
Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Kristine R, Broglio, Donald A, Berry
openaire   +2 more sources

Progression-free survival analysis based on whether a complete response was attained.

, 2021
Progression-free survival analysis based on whether a complete response was attained.
Elvina Almuradova (11663234), Merve Guner Oytun (11663231), Mustafa Harman (11663237), Ruchan Uslu (816262), Gulcan Bulut (11663228), Bulent Karabulut (11663240)   +5 more
core   +2 more sources

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

Clinical Characteristics, Course, and Long-Term Outcomes in Patients with Talaromyces marneffei Infection: A 10-Year Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu, Meifang Wei, Rong Xiao, Xiaona Liang, Siqiao Liang, Nan Ma, Siyao Wu, Yan Ning, Jingmin Deng, Meiling Yang, Quanfang Chen, Wen Zeng, Meihua Li, Xiaokai Feng, Zhiyi He   +14 more
doaj   +1 more source

Progression-free survival and overall survival of adult and pediatric patients with intracranial germinoma.

, 2022
Progression-free survival and overall survival of adult and pediatric patients with intracranial germinoma.
Chun-Fu Lin (12174572), Yee Chao (804364), Muh-Lii Liang (11204487), Keng-Li Lan (1459669), Tai-Tong Wong (48446), Feng-Chi Chang (435054), Yu-Mei Kang (12174569), Yi-Yen Lee (271429), Shih-Chieh Lin (63678), Hsin-Hung Chen (789932), Sanford P. C. Hsu (3177300), Yi-Wei Chen (48440)   +11 more
core   +1 more source

Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma

Cancer Treatment and Research Communications, 2021
Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Manasi Sheth, Jinnie Ko
doaj   +1 more source